The present invention relates to new substituted xanthines of general
formula ##STR00001## wherein R.sup.1, R.sup.2 and X are defined as in
the claims, the tautomers, the enantiomers, the diastereomers, the
mixtures thereof and the salts thereof, which have valuable
pharmacological properties, particularly an inhibiting effect on the
activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).